본문 바로가기
KERD
논문KCI 등재

기능성 소화불량증의 임상 진료 지침 개정안 2020

Clinical Practice Guidelines for the Treatment of Functional Dyspepsia in Korea

김성은|강승주|박종규|정혜경|이주엽|임현철|정경원|김준성|백명기|신정은|신철민|송경호|권중구|방기배|오정환|태정현|대한소화기기능성질환･운동학회 기능성 소화불량증위원회⋅진료지침위원회
대한내과학회 (The Korean Association Of Internal Medicine)|2021.04|대한내과학회지 (The Korean Journal of Medicine)|제96권 제2호|pp. 116-138|DOI https://doi.org/10.3904/kjm.2021.96.2.116

2

조회

0

다운로드

14

인용

0

참고문헌

키워드

GuidelineEvidence-based medicineDyspepsiaEndoscopyProton pump inhibitors
주제분류내과학

초록

Background/Aims: Functional dyspepsia (FD) is a chronic upper gastrointestinal symptom complex that routine diagnostic work-up, such as endoscopy, blood laboratory analysis, or radiological examination, fails to identify a cause for. It is highly prevalent in the Korean population, and its response to the various available therapeutic strategies is only modest because of the heterogeneous nature of its pathogenesis. We constituted a guidelines development committee to review the existing guidelines on the management of FD. Methods: This committee drafted statements and conducted a systematic review and meta-analysis of various studies, guidelines, and randomized control trials. External review was also conducted by selected experts. These clinical practice guidelines for FD were developed based on evidence recently accumulated with the revised version of FD guidelines released in 2011 by the Korean Society of Neurogastroenterology and Motility. Results: These guidelines apply to adults with chronic symptoms of FD and include the diagnostic role of endoscopy, Helicobacter pylori screening, and systematic review and meta-analyses of the various treatment options for FD (proton pump inhibitors, Helicobacter pylori eradication, and tricyclic antidepressants), especially according to the FD subtype. Conclusions: The purpose of these new guidelines is to aid understanding, diagnosis, and treatment of FD, and the targets of the guidelines are clinicians, healthcare workers at the forefront of patient care, patients, and medical students. The guidelines will continue to be revised and updated periodically.

Abstract

Background/Aims: Functional dyspepsia (FD) is a chronic upper gastrointestinal symptom complex that routine diagnostic work-up, such as endoscopy, blood laboratory analysis, or radiological examination, fails to identify a cause for. It is highly prevalent in the Korean population, and its response to the various available therapeutic strategies is only modest because of the heterogeneous nature of its pathogenesis. We constituted a guidelines development committee to review the existing guidelines on the management of FD. Methods: This committee drafted statements and conducted a systematic review and meta-analysis of various studies, guidelines, and randomized control trials. External review was also conducted by selected experts. These clinical practice guidelines for FD were developed based on evidence recently accumulated with the revised version of FD guidelines released in 2011 by the Korean Society of Neurogastroenterology and Motility. Results: These guidelines apply to adults with chronic symptoms of FD and include the diagnostic role of endoscopy, Helicobacter pylori screening, and systematic review and meta-analyses of the various treatment options for FD (proton pump inhibitors, Helicobacter pylori eradication, and tricyclic antidepressants), especially according to the FD subtype. Conclusions: The purpose of these new guidelines is to aid understanding, diagnosis, and treatment of FD, and the targets of the guidelines are clinicians, healthcare workers at the forefront of patient care, patients, and medical students. The guidelines will continue to be revised and updated periodically.

참고문헌 (148)

  1. Tack J, "Functional gastroduodenal disorders", Gastroenterology, 130, pp.1466~1479 (2006)
  2. Stanghellini V, "Gastroduodenal disorders", Gastroenterology, 150, pp.1380~1392 (2016)
  3. Sugano K, "Kyoto global consensus report on Helicobacter pylori gastritis", Gut, 64, pp.1353~1367 (2015)
  4. Hooi JKY, "Global prevalence of Helicobacter pylori infection : systematic review and meta-analysis", Gastroenterology, 153, pp.420~429 (2017)
  5. 김범진, "Online Registry for Nationwide Database of Current Trend of Helicobacter pylori Eradication in Korea: Interim Analysis", Journal of Korean Medical Science, 31(8), pp.1246~1253 (2016), 대한의학회
  6. Bak YT, "Evidence based guideline for diagnosis and treatment : therapeutic guideline for GERD", Kor J Neurogastroenterol Motil, 11, pp.13~17 (2005)
  7. 지삼룡, "기능성 소화불량증 치료에 관한 임상진료지침", 대한소화기학회지, 57(2), pp.67~81 (2011), 대한소화기학회
  8. Jung Hwan Oh, "Clinical Practice Guidelines for Functional Dyspepsia in Korea", Journal of Neurogastroenterology and Motility (JNM), 26(1), pp.29~50 (2020), 대한소화기 기능성질환∙운동학회[DOI]
  9. Higgins JP, "The Cochrane Collaboration's tool for assessing risk of bias in randomised trials", BMJ, 343, pp.d5928~ (2011)
  10. "GRADE handbook for grading quality of evidence and strength of recommendations" (2013)[URL]
  11. Kyung Ho Song, "Clinical Practice Guidelines for Irritable Bowel Syndrome in Korea, 2017 Revised Edition", Journal of Neurogastroenterology and Motility (JNM), 24(2), pp.197~215 (2018), 대한소화기 기능성질환∙운동학회[DOI]
  12. Malfertheiner P, "Management of Helicobacter pylori infection-the Maastricht V", Florence Consensus Report, 2017, pp.66, 6~30
  13. "Gastro-oesophageal reflux disease and dyspepsia in adults: investigation and management" (2014)[URL]
  14. Miwa H, "Evidence-based clinical practice guidelines for functional dyspepsia", J Gastroenterol, 50, pp.125~139 (2015)
  15. Talley NJ, "Management guidelines for uninvestigated and functional dyspepsia in the Asia-Pacific region : first Asian Pacific working party on functional dyspepsia", J Gastroenterol Hepatol, 13, pp.335~353 (1998)
  16. Talley NJ, "Practice Parameters Committee of the American College of Gastroenterology. Guidelines for the management of dyspepsia", Am J Gastroenterol, 100, pp.2324~2337 (2005)
  17. Moayyedi P, "ACG and CAG clinical guideline : management of dyspepsia", Am J Gastroenterol, 112, pp.988~1013 (2017)
  18. Zhao B, "Efficacy of Helicobacter pylori eradication therapy on functional dyspepsia : a meta-analysis of randomized controlled studies with 12-month follow-up", J Clin Gastroenterol, 48, pp.241~247 (2014)
  19. Lassen AT, "Helicobacter pylori test and eradicate versus prompt endoscopy for management of dyspeptic patients: 6.7 year follow up of a randomised trial", Gut, 53, pp.1758~1763 (2004)
  20. Lassen AT, "Helicobacter pylori test-and-eradicate versus prompt endoscopy for management of dyspeptic patients : a randomised trial", Lancet, 356, pp.455~460 (2000)
  21. Bytzer P, "Empirical H2-blocker therapy or prompt endoscopy in management of dyspepsia", Lancet, 343, pp.811~816 (1994)
  22. Laheij RJ, "Randomized controlled trial of omeprazole or endoscopy in patients with persistent dyspepsia : a cost-effectiveness analysis", Aliment Pharmacol Ther, 12, pp.1249~1256 (1998)
  23. Li XB, "Helicobacter pylori"test-and-treat"strategy is not suitable for the management of patients with uninvestigated dyspepsia in Shanghai", Scand J Gastroenterol, 40, pp.1028~1031 (2005)
  24. Liou JM, "The optimal age threshold for screening upper endoscopy for uninvestigated dyspepsia in Taiwan, an area with a higher prevalence of gastric cancer in young adults", Gastrointest Endosc, 61, pp.819~825 (2005)
  25. Aesun Shin, "Gastric Cancer Epidemiology in Korea", Journal of Gastric Cancer, 11(3), pp.135~140 (2011), 대한위암학회
  26. Song M, "Age and sex interactions in gastric cancer incidence and mortality trends in Korea", Gastric Cancer, 18, pp.580~589 (2015)
  27. Hwang IR, "Can Helicobacter pylori serology predict non-ulcer dyspepsia in young dyspeptic patients?", Clin Endosc, 21, pp.696~703 (2000)
  28. Talley NJ, "Functional dyspepsia", N Engl J Med, 373, pp.1853~1863 (2015)
  29. Suzuki H, "Helicobacter pylori infection in functional dyspepsia", Nat Rev Gastroenterol Hepatol, 10, pp.168~174 (2013)
  30. Delaney B, "Initial management strategies for dyspepsia", Cochrane Database Syst Rev, 4, pp.CD001961~ (2005)
  31. Harvey RF, "Clinical trial : prolonged beneficial effect of Helicobacter pylori eradication on dyspepsia consultations-the Bristol Helicobacter Project", Aliment Pharmacol Ther, 32, pp.394~400 (2010)
  32. Lee JH, "Seroprevalence of Helicobacter pylori in Korea: a multicenter, nationwide study conducted in 2015 and 2016", Helicobacter, 23, pp.e12463~ (2018)
  33. Eusebi LH, "Epidemiology of Helicobacter pylori infection", Helicobacter, 19(Suppl 1), pp.1~5 (2014)
  34. Talley NJ, "American Gastroenterological Association technical review on the evaluation of dyspepsia", Gastroenterology, 129, pp.1756~1780 (2005)
  35. Veldhuyzen van Zanten SJ, "Evidence-based recommendations for short-and long-term management of uninvestigated dyspepsia in primary care : an update of the Canadian Dyspepsia Working Group(CanDys)clinical management tool", Can J Gastroenterol, 19, pp.285~303 (2005)
  36. Moayyedi P, "Can the clinical history distinguish between organic and functional dyspepsia?", JAMA, 295, pp.1566~1576 (2006)
  37. 정규원, "Prediction of Cancer Incidence and Mortality in Korea, 2018", Cancer Research and Treatment, 50(2), pp.317~323 (2018), 대한암학회
  38. Chen SL, "Systematic review with meta-analysis : prompt endoscopy as the initial management strategy for uninvestigated dyspepsia in Asia", Aliment Pharmacol Ther, 41, pp.239~252 (2015)
  39. Miwa H, "Asian consensus report on functional dyspepsia", J Gastroenterol Hepatol, 27, pp.626~641 (2012)
  40. Ryu E, "Symptom clusters and quality of life in Korean patients with hepatocellular carcinoma", Cancer Nurs, 33, pp.3~10 (2010)
  41. Son HJ, "Hypersensitivity to acid in ulcer-like functional dyspepsia", Korean J Intern Med, 12, pp.188~192 (1997)
  42. Samsom M, "Abnormal clearance of exogenous acid and increased acid sensitivity of the proximal duodenum in dyspeptic patients", Gastroenterology, 116, pp.515~520 (1999)
  43. 이광재, "Duodenal Implications in the Pathophysiology of Functional Dyspepsia", Journal of Neurogastroenterology and Motility (JNM), 16(3), pp.251~257 (2010), 대한소화기 기능성질환∙운동학회
  44. Pinto-Sanchez MI, "Proton pump inhibitors for functional dyspepsia", Cochrane Database Syst Rev, 11, pp.CD011194~ (2017)
  45. Gerson LB, "A prospective study of oesophageal 24-h ambulatory pH monitoring in patients with functional dyspepsia", Dig Liver Dis, 37, pp.87~91 (2005)
  46. van Zanten SV, "Esomeprazole 40 mg once a day in patients with functional dyspepsia : the randomized, placebo-controlled"ENTER"trial", Am J Gastroenterol, 101, pp.2096~2106 (2006)
  47. Talley NJ, "Randomized-controlled trial of esomeprazole in functional dyspepsia patients with epigastric pain or burning : does a 1-week trial of acid suppression predict symptom response?", Aliment Pharmacol Ther, 26, pp.673~682 (2007)
  48. van Rensburg C, "Efficacy and safety of pantoprazole 20 mg once daily treatment in patients with ulcer-like functional dyspepsia", Curr Med Res Opin, 24, pp.2009~2018 (2008)
  49. Fletcher J, "BMI is superior to symptoms in predicting response to proton pump inhibitor : randomised trial in patients with upper gastrointestinal symptoms and normal endoscopy", Gut, 60, pp.442~448 (2011)
  50. Suzuki H, "Effect of lansoprazole on the epigastric symptoms of functional dyspepsia(ELF study) : a multicentre, prospective, randomized, double-blind, placebo-controlled clinical trial", United European Gastroenterol J, 1, pp.445~452 (2013)
  51. Iwakiri R, "Randomised clinical trial : rabeprazole improves symptoms in patients with functional dyspepsia in Japan", Aliment Pharmacol Ther, 38, pp.729~740 (2013)
  52. Majewski M, "Gastric pH and therapeutic responses to exsomeprazole in patients with functional dyspepsia : potential clinical implications", Am J Med Sci, 352, pp.582~592 (2016)
  53. Talley NJ, "Efficacy of omeprazole in functional dyspepsia : double-blind, randomized, placebo-controlled trials(the Bond and Opera studies)", Aliment Pharmacol Ther, 12, pp.1055~1065 (1998)
  54. Hiroto Miwa, "Asian Consensus Report on Functional Dyspepsia", Journal of Neurogastroenterology and Motility (JNM), 18(2), pp.150~168 (2012), 대한소화기 기능성질환∙운동학회[DOI]
  55. Syam AF, "National consensus on management of dyspepsia and Helicobacter pylori infection", Acta Med Indones, 49, pp.279~287 (2017)
  56. Moayyedi P, "The efficacy of proton pump inhibitors in nonulcer dyspepsia : a systematic review and economic analysis", Gastroenterology, 127, pp.1329~1337 (2004)
  57. Pinto-Sanchez MI, "Proton pump inhibitors for functional dyspepsia", Cochrane Database Syst Rev., 3, pp.CD011194~ (2017)
  58. Talley NJ, "Functional dyspepsia", Aust Prescr, 40, pp.209~213 (2017)
  59. Tack J, "Pathophysiology and treatment of functional dyspepsia", Gastroenterology, 127, pp.1239~1255 (2004)
  60. Moayyedi P, "Pharmacological interventions for non-ulcer dyspepsia", Cochrane Database Syst Rev, 4, pp.CD001960~ (2006)
  61. Miner PB Jr, "Comparison of gastric pH with omeprazole magnesium 20.6 mg (Prilosec OTC) o.m. famotidine 10 mg (Pepcid AC) b.d. and famotidine 20 mg b.d. over 14 days of treatment", Aliment Pharmacol Ther, 25, pp.103~109 (2007)
  62. McRorie JW, "Histamine2-receptor antagonists : Rapid development of tachyphylaxis with repeat dosing", World J Gastrointest Pharmacol Ther, 5, pp.57~62 (2014)
  63. Hojo M, "A randomized, double-blind, pilot study of the effect of famotidine on acotiamide treatment for functional dyspepsia", Digestion, 96, pp.5~12 (2017)
  64. Park KH, "Ranitidine-induced anaphylaxis : clinical features, cross-reactivity, and skin testing", Clin Exp Allergy, 46, pp.631~639 (2016)
  65. Veldhuyzen van Zanten SJ, "Efficacy of cisapride and domperidone in functional(nonulcer)dyspepsia : a meta-analysis", Am J Gastroenterol, 96, pp.689~696 (2001)
  66. Eamonn M M Quigley, "Prokinetics in the Management of Functional Gastrointestinal Disorders", Journal of Neurogastroenterology and Motility (JNM), 21(3), pp.330~336 (2015), 대한소화기 기능성질환∙운동학회[DOI]
  67. Huang X, "Itopride therapy for functional dyspepsia : a meta-analysis", World J Gastroenterol, 18, pp.7371~7377 (2012)
  68. Talley NJ, "Itopride in functional dyspepsia : results of two phase III multicentre, randomised, double-blind, placebo-controlled trials", Gut, 57, pp.740~746 (2008)
  69. Kusunoki H, "Efficacy of mosapride citrate in proximal gastric accommodation and gastrointestinal motility in healthy volunteers : a double-blind placebo-controlled ultrasonographic study", J Gastroenterol, 45, pp.1228~1234 (2010)
  70. Hallerbäck BI, "Dose finding study of mosapride in functional dyspepsia : a placebo-controlled, randomized study", Aliment Pharmacol Ther, 16, pp.959~967 (2002)
  71. 조유경, "기능성 소화불량증의 삶의 질에 대한 모사프리드의 효과", 대한소화기학회지, 43(3), pp.160~167 (2004), 대한소화기학회
  72. Bang CS, "Mosapride treatment for functional dyspepsia : a meta-analysis", J Gastroenterol Hepatol, 30, pp.28~42 (2015)
  73. Hongo M, "Large-scale randomized clinical study on functional dyspepsia treatment with mosapride or teprenone : Japan Mosapride Mega-Study(JMMS)", J Gastroenterol Hepatol, 27, pp.62~68 (2012)
  74. Kinoshita Y, "Effects of famotidine, mosapride and tandospirone for treatment of functional dyspepsia", Aliment Pharmacol Ther., 21(Suppl 2), pp.37~41 (2005)
  75. Otaka M, "New strategy of therapy for functional dyspepsia using famotidine, mosapride and amitriptyline", Aliment Pharmacol Ther, 21(Suppl 2), pp.42~46 (2005)
  76. Hyuk Yoon, "Efficacy and Safety of UI05MSP015CT in Functional Dyspepsia: A Randomized, Controlled Trial", Gut and Liver, 12(5), pp.516~522 (2018), 거트앤리버 소화기연관학회협의회
  77. Hiyama T, "Meta-analysis of the effects of prokinetic agents in patients with functional dyspepsia", J Gastroenterol Hepatol, 22, pp.304~310 (2007)
  78. Pittayanon R, "Prokinetics for functional dyspepsia : a systematic review and meta-analysis of randomized control trials", Am J Gastroenterol, 114, pp.233~243 (2019)
  79. Yang YJ, "Prokinetics for the treatment of functional dyspepsia : bayesian network meta-analysis", BMC Gastroenterol, 17, pp.83~ (2017)
  80. 정혜경, "Efficacy of DA-9701 (Motilitone) in Functional Dyspepsia Compared to Pantoprazole: A Multicenter, Randomized, Double-blind, Non-inferiority Study", Journal of Neurogastroenterology and Motility (JNM), 22(2), pp.254~263 (2016), 대한소화기 기능성질환∙운동학회[DOI]
  81. Parkman HP, "American Gastroenterological Association technical review on the diagnosis and treatment of gastroparesis", Gastroenterology, 127, pp.1592~1622 (2004)
  82. Tatsuta M, "Effect of treatment with cisapride alone or in combination with domperidone on gastric emptying and gastrointestinal symptoms in dyspeptic patients", Aliment Pharmacol Ther, 6, pp.221~228 (1992)
  83. Aziz I, "Epidemiology, clinical characteristics, and associations for symptom-based Rome IV functional dyspepsia in adults in the USA, Canada, and the UK : a cross-sectional population-based study", Lancet Gastroenterol Hepatol, 3, pp.252~262 (2018)
  84. Tack J, "Acotiamide(Z-338, YM443), a new drug for the treatment of functional dyspepsia", Expert Opin Investig Drugs, 20, pp.701~712 (2011)
  85. Matsueda K, "A placebo-controlled trial of acotiamide for meal-related symptoms of functional dyspepsia", Gut, 61, pp.821~828 (2012)
  86. Nakamura K, "A double-blind placebo controlled study of acotiamide hydrochloride for efficacy on gastrointestinal motility of patients with functional dyspepsia", J Gastroenterol, 52, pp.602~610 (2017)
  87. Xiao G, "Efficacy and safety of acotiamide for the treatment of functional dyspepsia : systematic review and meta-analysis", ScientificWorldJournal, 2014, pp.541950~ (2014)
  88. Tack J, "Long-term safety and efficacy of acotiamide in functional dyspepsia (postprandial distress syndrome)-results from the European phase 3 open-label safety trial", Neurogastroenterol Motil, 30, pp.e13284~ (2018)
  89. Shinozaki S, "The effect of acotiamide on epigastric pain syndrome and postprandial distress syndrome in patients with functional dyspepsia", J Med Invest, 63, pp.230~235 (2016)
  90. Arts J, "Influence of erythromycin on gastric emptying and meal related symptoms in functional dyspepsia with delayed gastric emptying", Gut, 54, pp.455~460 (2005)
  91. Janssens J, "Improvement of gastric emptying in diabetic gastroparesis by erythromycin. Preliminary studies", N Engl J Med, 322, pp.1028~1031 (1990)
  92. Basch E, "Antiemetics : American Society of Clinical Oncology clinical practice guideline update", J Clin Oncol, 29, pp.4189~4198 (2011)
  93. "Domperidone: ventricular arrhythmia and sudden death (continued)", Prescrire Int, 21, pp.183~ (2012)
  94. Frommeyer G, "Severe proarrhythmic potential of the antiemetic agents ondansetron and domperidone", Cardiovasc Toxicol, 17, pp.451~457 (2017)
  95. Shin HW, "Levosulpiride-induced movement disorders", Mov Disord, 24, pp.2249~2253 (2009)
  96. Du LJ, "Helicobacter pylori eradication therapy for functional dyspepsia : systematic review and meta-analysis", World J Gastroenterol, 22, pp.3486~3495 (2016)
  97. McColl K, "Symptomatic benefit from eradicating Helicobacter pylori infection in patients with nonulcer dyspepsia", N Engl J Med, 339, pp.1869~1874 (1998)
  98. Blum AL, "Lack of effect of treating Helicobacter pylori infection in patients with nonulcer dyspepsia. Omeprazole plus Clarithromycin and Amoxicillin Effect One Year after Treatment (OCAY) Study Group", N Engl J Med, 339, pp.1875~1881 (1998)
  99. Talley NJ, "Absence of benefit of eradicating Helicobacter pylori in patients with nonulcer dyspepsia", N Engl J Med, 341, pp.1106~1111 (1999)
  100. Talley NJ, "Eradication of Helicobacter pylori in functional dyspepsia: randomised double blind placebo controlled trial with 12 months' follow up. The Optimal Regimen Cures Helicobacter Induced Dyspepsia (ORCHID)Study Group", BMJ, 318, pp.833~837 (1999)
  101. Koskenpato J, "Helicobacter pylori eradication and standardized 3-month omeprazole therapy in functional dyspepsia", Am J Gastroenterol, 96, pp.2866~2872 (2001)
  102. Hsu PI, "Eradication of Helicobacter pylori prevents ulcer development in patients with ulcer-like functional dyspepsia", Aliment Pharmacol Ther, 15, pp.195~201 (2001)
  103. Bruley Des Varannes S, "There are some benefits for eradicating Helicobacter pylori in patients with non-ulcer dyspepsia", Aliment Pharmacol Ther, 15, pp.1177~1185 (2001)
  104. Froehlich F, "Helicobacter pylori eradication treatment does not benefit patients with nonulcer dyspepsia", Am J Gastroenterol, 96, pp.2329~2336 (2001)
  105. Chiba N, "Treating Helicobacter pylori infection in primary care patients with uninvestigated dyspepsia : the Canadian adult dyspepsia empiric treatment-Helicobacter pylori positive(CADET-Hp)randomised controlled trial", BMJ, 324, pp.1012~1016 (2002)
  106. Veldhuyzen van Zanten S, "Absence of symptomatic benefit of lansoprazole, clarithromycin, and amoxicillin triple therapy in eradication of Helicobacter pylori positive, functional(nonulcer)dyspepsia", Am J Gastroenterol, 98, pp.1963~1969 (2003)
  107. Malfertheiner P, "Helicobacter pylori eradication is beneficial in the treatment of functional dyspepsia", Aliment Pharmacol Ther, 18, pp.615~625 (2003)
  108. Gisbert JP, "Lack of benefit of treating Helicobacter pylori infection in patients with functional dyspepsia. Randomized one-year follow-up study", Hepatogastroenterology, 51, pp.303~308 (2004)
  109. Mazzoleni LE, "Clinical outcomes of eradication of Helicobacter pylori in nonulcer dyspepsia in a population with a high prevalence of infection : results of a 12-month randomized, double blind, placebo-controlled study", Dig Dis Sci, 51, pp.89~98 (2006)
  110. Ang TL, "Helicobacter pylori eradication versus prokinetics in the treatment of functional dyspepsia : a randomized, double-blind study", J Gastroenterol, 41, pp.647~653 (2006)
  111. Gwee KA, "The response of Asian patients with functional dyspepsia to eradication of Helicobacter pylori infection", Eur J Gastroenterol Hepatol, 21, pp.417~424 (2009)
  112. Mazzoleni LE, "Helicobacter pylori eradication in functional dyspepsia : HEROES trial", Arch Intern Med, 171, pp.1929~1936 (2011)
  113. Sodhi JS, "Prevalence of Helicobacter pylori infection and the effect of its eradication on symptoms of functional dyspepsia in Kashmir, India", J Gastroenterol Hepatol, 28, pp.808~813 (2013)
  114. Yazdanbod A, "Effect of Helicobacter pylori eradication in Iranian patients with functional dyspepsia : a prospective, randomized, placebo-controlled trial", Arch Med Sci, 11, pp.964~969 (2015)
  115. Tack J, "Role of impaired gastric accommodation to a meal in functional dyspepsia", Gastroenterology, 115, pp.1346~1352 (1998)
  116. Van Oudenhove L, "Influence of buspirone on gastric sensorimotor function in man", Aliment Pharmacol Ther, 28, pp.1326~1333 (2008)
  117. Tack J, "Efficacy of buspirone, a fundus-relaxing drug, in patients with functional dyspepsia", Clin Gastroenterol Hepatol, 10, pp.1239~1245 (2012)
  118. Miwa H, "Efficacy of the 5-HT1A agonist tandospirone citrate in improving symptoms of patients with functional dyspepsia : a randomized controlled trial", Am J Gastroenterol, 104, pp.2779~2787 (2009)
  119. Tack J, "The influence of cisapride on gastric tone and the perception of gastric distension", Aliment Pharmacol Ther, 12, pp.761~766 (1998)
  120. Tack J, "Influence of tegaserod on proximal gastric tone and on the perception of gastric distention in functional dyspepsia", Neurogastroenterol Motil, 23, pp.e32~e39 (2011)
  121. Amano T, "Effect of 5-hydroxytryptamine receptor 4 agonist mosapride on human gastric accommodation", Neurogastroenterol Motil, 27, pp.1303~1309 (2015)
  122. Kusunoki H, "Therapeutic efficacy of acotiamide in patients with functional dyspepsia based on enhanced postprandial gastric accommodation and emptying : randomized controlled study evaluation by real-time ultrasonography", Neurogastroenterol Motil, 24, pp.540~ (2012)
  123. Lacy BE, "Effects of antidepressants on gastric function in patients with functional dyspepsia", Am J Gastroenterol, 113, pp.216~224 (2018)
  124. Lu Y, "Antidepressants in the treatment of functional dyspepsia: a systematic review and meta-analysis", PLoS One, 11, pp.e0157798~ (2016)
  125. Ford AC, "Efficacy of psychotropic drugs in functional dyspepsia : systematic review and meta-analysis", Gut, 66, pp.411~420 (2017)
  126. Cheong PK, "Low-dose imipramine for refractory functional dyspepsia : a randomised, double-blind, placebo-controlled trial", Lancet Gastroenterol Hepatol, 3, pp.837~844 (2018)
  127. Kaosombatwattana U, "Efficacy and safety of nortriptyline in functional dyspepsia in Asians : a randomized double-blind placebo-controlled trial", J Gastroenterol Hepatol, 33, pp.411~417 (2018)
  128. Talley NJ, "Effect of amitriptyline and escitalopram on functional dyspepsia : a multicenter, randomized controlled study", Gastroenterology, 149, pp.340~349 (2015)
  129. Jaafar MH, "Efficacy of rebamipide in organic and functional dyspepsia : a systematic review and meta-analysis", Dig Dis Sci, 63, pp.1250~1260 (2018)
  130. Gudjónsson H, "Efficacy of sucralfate in treatment of non-ulcer dyspepsia. A double-blind placebo-controlled study", Scand J Gastroenterol, 28, pp.969~972 (1993)
  131. Kairaluoma MI, "Sucralfate versus placebo in treatment of non-ulcer dyspepsia", Am J Med, 83, pp.51~55 (1987)
  132. Moayyedi P, "Systematic review : antacids, H2-receptor antagonists, prokinetics, bismuth and sucralfate therapy for non-ulcer dyspepsia", Aliment Pharmacol Ther, 17, pp.1215~1227 (2003)
  133. Holtmann G, "Randomised double-blind comparison of simethicone with cisapride in functional dyspepsia", Aliment Pharmacol Ther, 13, pp.1459~1465 (1999)
  134. Holtmann G, "A randomized placebo-controlled trial of simethicone and cisapride for the treatment of patients with functional dyspepsia", Aliment Pharmacol Ther, 16, pp.1641~1648 (2002)
  135. Adibi P, "Association of anxiety, depression, and psychological distress in people with and without functional dyspepsia", Adv Biomed Res, 5, pp.195~ (2016)
  136. Calvert EL, "Long-term improvement in functional dyspepsia using hypnotherapy", Gastroenterology, 123, pp.1778~1785 (2002)
  137. Haug TT, "Psychotherapy in functional dyspepsia", J Psychosom Res, 38, pp.735~744 (1994)
  138. Hamilton J, "A randomized controlled trial of psychotherapy in patients with chronic functional dyspepsia", Gastroenterology, 119, pp.661~669 (2000)
  139. Soo S, "A systematic review of psychological therapies for nonulcer dyspepsia", Am J Gastroenterol, 99, pp.1817~1822 (2004)
  140. Haag S, "Is there a benefit from intensified medical and psychological interventions in patients with functional dyspepsia not responding to conventional therapy?", Aliment Pharmacol Ther, 25, pp.973~986 (2007)
  141. Orive M, "A randomized controlled trial of a 10 week group psychotherapeutic treatment added to standard medical treatment in patients with functional dyspepsia", J Psychosom Res, 78, pp.563~568 (2015)
  142. Chen Y, "Association of psychological characteristics and functional dyspepsia treatment outcome : a case-control study", Gastroenterol Res Pract, 2016, pp.5984273~ (2016)
  143. Barbera R, "Nutrient-specific modulation of gastric mechanosensitivity in patients with functional dyspepsia", Dig Dis Sci, 40, pp.1636~1641 (1995)
  144. Pilichiewicz AN, "Relationship between symptoms and dietary patterns in patients with functional dyspepsia", Clin Gastroenterol Hepatol, 7, pp.317~322 (2009)
  145. Pilichiewicz AN, "Functional dyspepsia is associated with a greater symptomatic response to fat but not carbohydrate, increased fasting and postprandial CCK, and diminished PYY", Am J Gastroenterol, 103, pp.2613~2623 (2008)
  146. Feinle-Bisset C, "Dietary and lifestyle factors in functional dyspepsia", Nat Rev Gastroenterol Hepatol, 10, pp.150~157 (2013)
  147. Carvalho RV, "Food intolerance, diet composition, and eating patterns in functional dyspepsia patients", Dig Dis Sci, 55, pp.60~65 (2010)
  148. Mullan A, "Food and nutrient intakes and eating patterns in functional and organic dyspepsia", Eur J Clin Nutr, 48, pp.97~105 (1994)

관련 논문AI추천

Failure of a Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effi cacy of H. pylori Eradication in H. pylori -Infected Patients with Functional Dyspepsia김광하, 김재규, 박무인, 박병주, 박수경, 설상영, 양창헌, 이상우, 이상인, 전성우, 최석채, 홍수진, Dong Ho Lee, In Kyung Sung거트앤리버 소화기연관학회협의회 · Gut and Liver2011 · 제5권 제4호기능성 소화불량 환자의 증상, 위내시경 소견 및 위전도 지표 간 연관성: 후향적 단면 연구김소연, 박규태한의병리학회 · 동의생리병리학회지2025 · 제39권 제6호Functional dyspepsia: new insights into pathogenesis and therapyNicholas J Talley대한내과학회 · The Korean Journal of Internal Medicine2016 · 제31권 제3호헬리코박터 제균 요법이 기능성 소화불량증 환자와 소화성 궤양 환자의 증상 호전에 미치는 효과감창우, 고근준, 김재영, 박태운, 이은재, 이재은, 조현근, 최창환, 한기준, 홍성일대한내과학회 · 대한내과학회지2006 · 제71권 제2호과민성장증후군 치료전략: 언제, 어떤 약을 사용할 것인가?김정환, 성인경대한내과학회 · 대한내과학회지2014 · 제86권 제6호Evidence based guidelines for the treatment of Helicobacter pylori infection in Korea 2020김지현, 이용찬, 임현철, Cheol Min Shin, Hye-Kyung Jung, Hyo-Joon Yang, Il Ju Choi, Jae Gyu Kim, Jae Myung Park, Miyoung Choi, Seon-Young Park, Seung Joo Kang, Sung Eun Kim, Su Youn Nam, Woon Geon Shin대한내과학회 · The Korean Journal of Internal Medicine2021 · 제36권 제4호

이 간행물의 다른 논문 (5건)

비알코올성 지방간 질환과 소포체 스트레스송명준pp. 92-100췌장암 조기 진단을 위한 선별 검사장재혁pp. 110-115Nafcillin 투여에 따른 저칼륨혈증 1예이은경, 김소미, 이도현, 조종태, 이지은, 김석원pp. 139-142급성 대장염과 유사한 신종코로나 감염 1예김대진, 이재광, 정재권, 류한준, 김현수, 박창근, 박재석pp. 143-146폐결핵으로 치료 중 범혈구감소증으로 발현한 전신홍반루푸스강형구, 구현경, 박혜경, 이성순, 강지은, 박소희, 배원pp. 147-151
원문 보기